

Johnson & Johnson Innovative Medicine Pipeline – Key Events in 2023*

POTENTIAL APPROVALS US/EU

- ✓ US **AKEEGA (niraparib/abiraterone)**
- ✓ EU **L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)**

- ✓ US **TALVEY (talquetamab)**
- ✓ EU **Relapsed Refractory Multiple Myeloma**

- ✓ US **ERLEADA (apalutamide)**
- ✓ EU **Tablet Reduction**

- ✓ EU **TECVAYLI (teclistamab)**
- Relapsed Refractory Multiple Myeloma Biweekly Dosing

PLANNED SUBMISSIONS US/EU

- ✓ US **AKEEGA (niraparib/abiraterone)**
- L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)

- TALVEY (talquetamab)**
- ✓ EU **Relapsed Refractory Multiple Myeloma**

- ✓ US **BALVERSA (erdafitinib)**
- ✓ EU **Urothelial cancer (THOR)**

- ✓ US **CARVYKTI (ciltacabtagene autoleucel)**
- ✓ EU **Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)**

- ✓ US **EDURANT (rilpivirine)**
- ✓ EU **HIV pediatric 2-12 year old**

- OPSUMIT (macitentan)**
- ✓ EU **Pediatric pulmonary arterial hypertension**

- ✓ US **macitentan w/tadalafil FDC**
- ✓ EU **Pulmonary arterial hypertension**

- ✓ US **RYBREVANT (amivantamab)**
- ✓ EU **Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)**

- US **amivantamab / lazertinib**
- EU **Non Small Cell Lung Cancer 2L (MARIPOSA-2)**

- US **amivantamab / lazertinib**
- Non Small Cell Lung Cancer (MARIPOSA)

POTENTIAL CLINICAL DATA

Phase III

- ✓ **CARVYKTI (ciltacabtagene autoleucel)**
- Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

- ✓ **BALVERSA (erdafitinib)**
- Urothelial cancer (THOR)

- RYBREVANT (amivantamab)**
- Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

- IMBRUVICA (ibrutinib)**
- Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)

- amivantamab / lazertinib**
- Non Small Cell Lung Cancer 2L (MARIPOSA-2)

- amivantamab / lazertinib**
- Non Small Cell Lung Cancer (MARIPOSA)

- ✓ **macitentan w/tadalafil FDC**
- Pulmonary arterial hypertension (A DUE)

- ✓ **SPRAVATO (esketamine)**
- Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

- TREMFYA (guselkumab)**
- Crohn's Disease

- ✓ **TREMFYA (guselkumab)**
- Ulcerative Colitis Monotherapy

Phase I/II

- ✓ **TAR-200 (RIS/gemcitabine plus cetrelimab)**
- Non muscle invasive bladder cancer (SR-1 Early Data)

- TAR-210 (RIS/erdafitinib)**
- Non muscle invasive bladder cancer (Early Data)

- TAR-200 (RIS/gemcitabine plus cetrelimab)**
- Non muscle invasive bladder cancer (SunRISe-1 Update)

- ✓ **BALVERSA (erdafitinib)**
- Tumor Agnostic (RAGNAR)

- RYBREVANT (amivantamab)**
- Solid Tumors (GIC2001)

- ✓ **JNJ-2113**
- Psoriasis

- nipocalimab**
- Rheumatoid Arthritis

- ✓ **nipocalimab**
- Hemolytic disease of the fetus and newborn